medigraphic.com
Colegio de Medicina Interna de México.

2019, Número 6

<< Anterior Siguiente >>

Med Int Mex 2019; 35 (6)


Púrpura trombocitopénica trombótica

Morales-Montoya A

Idioma: Español
Referencias bibliográficas: 48
Paginas: 906-911
Archivo PDF: 352.51 Kb.


RESUMEN

La púrpura trombocitopénica trombótica es una enfermedad que forma parte de las microangiopatías trombóticas causada por la deficiencia o mal funcionamiento de la proteína ADAMTS13; tiene tres manifestaciones principales: crónica, idiopática o autoinmunitaria; esta última es la más común; sus manifestaciones clínicas son variables dependiendo del tiempo de evolución; van desde fiebre, fatiga, artralgias, dolor abdominal y lumbar hasta infarto de miocardio, alteraciones neurológicas, insuficiencia renal, accidente cerebrovascular isquémico y trombosis arterial y venosa. Debido a la complejidad y diversidad de manifestaciones y complicaciones que conlleva esta enfermedad, su diagnóstico y tratamiento oportuno y eficaz aún se dificultan un poco; sin embargo, ahora se cuenta con un tratamiento de primera línea que se basa principalmente en terapia de reemplazo de plasma, que es el más prescrito en la actualidad.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kremer JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers 2017;3:17020. doi: 10.1038/nrdp.2017.20.

  2. Knöbl P. Thrombotic thrombocytopenic purpura. Memo 2017;11:220-226. doi: 10.1007/s12254-018-0429-6.

  3. Birlutiu V, Birlutiu RM. Haemolytic-uremic syndrome due to infection with adenovirus: A case report and literature review. Medicine (Baltimore) 2018;97(7). doi: 10.1097/ MD.0000000000009895.

  4. Yap Y, Sathar J, Law KB, Zulkurnain PA, Edmund SC, Chang KM, et al. Clinical characteristics and outcomes of thrombotic microangiopathy in Malaysia. Blood Research 2018;53(2):130-137. doi: 10.5045/br.2018.53.2.130.

  5. Sridharan M, Go RS, Willrich MAV. Atypical hemolytic uremic syndrome: Review of clinical presentation, diagnosis and management. J Immunol Methods 2018;461:15-22. Doi: 10.1016/j.jim.2018.07.006.

  6. Neave L, Scully M. Microangiopathic hemolytic anemia in pregnancy. Transfus Med Rev 2018;32(4):230-236. doi: 10.1016/j.tmrv.2018.08.002.

  7. Gupta M, Feinberg BB, Burwick RM. Thrombotic microangiopathies of pregnancy: Differential diagnosis. Pregnancy Hypertens 2018;12:29-34. doi: 10.1016/j. preghy.2018.02.007.

  8. Plautz WE, Raval JS, Dyer MR, Rollins-Raval MA, Zuckerbraun BS, Neal MD. ADAMTS13: origins, applications, and prospects. Transfusion 2018;58(10):2453-2462. doi: 10.1111/trf.14804.

  9. Schelpe A, Orlando C, Ercig B, Geeroms C, Pareyn I, Vandeputte N, et al. Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13. Eur J Haematol 2018 May 15. doi: 10.1111/ ejh.13094.

  10. Joseph A, Rafat C, Zafrani L, Mariani-Kurkdjian P, Veyradier A, Hertig A, et al. Early differentiation of Shiga toxin-associated hemolytic uremic syndrome in critically ill adults with thrombotic microangiopathy syndromes. Crit Care Med 2018;46(9):e904-e911. doi: 10.1097/ CCM.0000000000003292.

  11. Caeiro Alves F, Aguiar R, Pessegueiro P, Pires C. Thrombotic microangiopathy associated with Mycoplasma pneumoniae infection. BMJ Case Rep 2018. doi: 10.1136/ bcr-2017-222582.

  12. Jodele S. Complement in pathophysiology and treatment of transplant-associated thrombotic microangiopathies. Semin Hematol 2018;55(3):159-166. doi: 10.1053/j.seminhematol. 2018.04.003.

  13. Özdemir BH, Ok Atılgan A, Yılmaz Akçay E, Özdemir G, Ayvazoğlu Soy E, Akdur A, et al. De novo thrombotic microangiopathy in renal transplant patients. Exp Clin Transplant 2018;16 Suppl 1(Suppl 1):131-135. doi: 10.6002/ ect.TOND-TDTD2017.P27.

  14. Atallah-Yunes SA, Soe MH. Drug-induced thrombotic microangiopathy due to cumulative toxicity of ixazomib. Case Rep Hematol 2018; 2018:7063145. doi: 10.1155/2018/7063145.

  15. Wang X, Zhang S, Li L, Hua J, Zhu L, Li L, Zhang G. Ticagrelor-induced thrombotic thrombocytopenic purpura: A case report and review of the literature. Medicine (Baltimore) 2018;97(26):e11206. doi: 10.1097/ MD.0000000000011206.

  16. Baysal M, Ümit EG, Sarıtaş F, Kodal NS, Demir AM. Drug induced thrombotic microangiopathy with certolizumab pegol. Balkan Med J 2018;35(5):398-399. doi: 10.4274/ balkanmedj.2017.1224.

  17. Demirsoy ET, Mehtap O, Atesoglu EB, Tarkun P, Eren N, Gedük A, et al. Dasatinib-induced immune mediatedthrombotic thrombocytopenic purpura. Transfus Apher Sci 2018;57(2):222-224. doi: 10.1016/j.transci.2018.02.003.

  18. Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, et al. Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune- mediated thrombotic thrombocytopenic purpura. Blood J 2017;130(4):466-471. doi: 10.1182/ blood-2016-12-758656.

  19. Masias C, Cataland SR. The role of ADAMTS13 testing in the diagnosis and management of thrombotic microangiopathies and thrombosis. Blood 2018;132(9):903-910. doi: 10.1182/blood-2018-02-791533.

  20. Bennett CM, Neunert C, Grace RF, Buchanan G, Imbach P, Vesely SK, et al. Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatr Blood Cancer 2017;65(1). doi: 10.1002/pbc.26736.

  21. Barbosa AM, Albuquerque R, Simoes CI, Saraiva FW, Gomes O, Da Silva MH, et al. Platelet count response to Helicobacter pylori eradication for idiopathic thrombocytopenic purpura in northeastern Brazil. Braz J Hematol Hemotherapy 2017. https://doi.org/10.1016/j.bjhh.2017.09.005.

  22. Cybulska A, Meintker L, Ringwald J, Krause SW. Measurements of immature platelets with haematology analysers are of limited value to separate immune thrombocytopenia from bone marrow failure. Br J Haematol 2017;177(4):612- 619. doi: 10.1111/bjh.14628.

  23. Phillips J, Henderson AC. Hemolytic anemia: evaluation and differential diagnosis. Am Fam Physician 2018;98(6):354- 361.

  24. Peyvani F, Scully M, Kremer JA, Knöbl P, Cataland S, De Beuf K, et al. Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemostasis 2017;15(7):1448-1452. doi: 10.1111/jth.13716.

  25. Ercig B, Wichapong K, Reutelingsperger CPM, Vanhoorelbeke K, Voorberg J, Nicolaes GAF. Insights into 3D structure of ADAMTS13: A stepping stone towards novel therapeutic treatment of thrombotic thrombocytopenic purpura. Thromb Haemost 2018;118(1):28-41. doi: 10.1160/TH17-06-0404.

  26. Atrash S, Sasapu A, Pandey S, Cottler-Fox M, Motwani P. Complement regulatory genetic mutations in the setting of autoimmune thrombotic thrombocytopenic purpura: a case series. Mayo Clin Proc Innov Qual Outcomes 2017;2(1):69-73. doi: 10.1016/j.mayocpiqo.2017.11.004.

  27. Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, et al. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Advances 2017;1(25):2414-2420. doi: 10.1182/bloodadvances.2017010942.

  28. Jia X, He Y, Ruan CG. Research advances of acquired thrombotic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2018;26(4) :1230-1234. http://dx.doi. org/10.7534/j.issn.1009-2137.2018.04.048.

  29. Pandey S, Cottler-Fox M. ADAMTS13 testing methodologies and thrombotic thrombocytopenic purpura (TTP): Conflicting results can pose a clinical dilemma. Ann Clin Lab Sci 2018;48(3):373-376.

  30. Bommer M, Wölfle-Guter M, Bohl S, Kuchenbauer F. The differential diagnosis and treatment of thrombotic microangiopathies. Dtsch Arztebl Int 2018;115(19) :327-334. doi: 10.3238/arztebl.2018.0327.

  31. Oka S, Nohgawa M. EB virus reactivation triggers thrombotic thrombocytopenic purpura in a healthy adult. Leuk Res Rep 2017;8:1-3. https://dx.doi.org/10.1016%2Fj. lrr.2017.06.001.

  32. Conboy E, Partain PI, Warad D, Kluge ML, et al. A severe case of congenital thrombotic thrombocytopenia purpura resulting from compound heterozygosity involving a novel ADAMTS13 pathogenic variant. J Pediatr Hematol Oncol 2018;40(1):60-62. doi: 10.1097/MPH.0000000000000895.

  33. Roose E, Schelpe AS, Joly BS, Peetermans M, Verhamme P, Voorberg J, et al. An open conformation of ADAMTS13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 2018;16(2):378-388. doi: 10.1111/jth.13922.

  34. South K, Freitas MO, Lane DA. A model for the conformational activation of the structurally quiescent metalloprotease ADAMTS13 by von Willebrand factor. J Biol Chem 2017;292(14):5760-5769. doi: 10.1074/jbc.M117.776732.

  35. Schapkaitz E, Schickerling TM. The diagnostic challenge of acquired thrombotic thrombocytopenic purpura in children: case report and review of the literature. Lab Med 2018;49(3):268-271. doi: 10.1093/labmed/lmy015.

  36. Nowak AA, O’Brien H, Henne P, Doerr A, Vanhoorelbeke K, Laffan MA, et al. ADAMTS13 glycans and conformationdependent activity. J Thromb Haemost 2017;15(6):1155- 1166. doi: 10.1111/jth.13688.

  37. Fidalgo T, Martinho P, Pinto CS, Oliveira AC, Salvado R, Borràs N, et al. Combined study of ADAMTS13 and complement genes in the diagnosis of thrombotic microangiopathies using next-generation sequencing. Res Pract Thromb Haemost 2017;1(1):69-80. https://doi. org/10.1002/rth2.12016.

  38. Sinkovits G, Szilágyi A, Farkas P, Inotai D, Szilvási A, Tordai A, et al. The role of human leukocyte antigen DRB1-DQB1 haplotypes in the susceptibility to acquired idiopathic thrombotic thrombocytopenic purpura. Human Immunol 2016. doi: 10.1016/j.humimm.2016.11.005.

  39. Momtaz M, Fayed A, Marzouk K, Shaker A. Therapeutic plasma exchange outcomes in Cairo university hospitals: 6 years experience. Ther Apher Dial 2018. doi: 10.1111/1744- 9987.12710.

  40. Takase K, Kada A, Iwasaki H, Yoshida I, Sawamura M, Yoshio N, et al. High-dose dexamethasone therapy as the initial treatment for idiopathic thrombocytopenic purpura: protocol for a multicenter, open-label, single arm trial. Acta Med Okayama 2018;72(2):197-201. doi: 10.18926/AMO/55863.

  41. Joly BS, Vanhoorelbeke K, Veyradier A. Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Intensive Care Med 2017;43(9):1398-1400. doi: 10.1007/ s00134-016-4662-3.

  42. Olson SR, Lu E, Sulpizio E, Shatzel JJ, Rueda JF, DeLoughery TG. When to stop eculizumab in complementmediated thrombotic microangiopathies. Am J Nephrol 2018;48(2):96-107. doi: 10.1159/000492033.

  43. Tagle R, Rivera G, Walbaum B, Sepúlveda RA. Atypical hemolytic uremic syndrome. Report of two cases treated with eculizumab. Rev Med Chil 2018;146(2):254-259. doi: 10.4067/s0034-98872018000200254.

  44. Vondrák K, Seeman T. Successful 7-year eculizumab treatment of plasmapheresis-resistant recurrent atypical hemolytic-uremic syndrome due to complement factor h hybrid gene: a case report. Transplant Proc 2018;50(3):967- 970. doi: 10.1016/j.transproceed.2018.02.012.

  45. Sasapu A, Cottler-Fox M, Motwani P. Acquired thrombotic thrombocytopenic purpura and atypical hemolytic uremic syndrome successfully treated with eculizumab. Proc (Bayl Univ Med Cent) 2017;30(2):182-183.

  46. Jestin M, Benhamou Y, Schelpe AS, Roose E, Provôt F, Galicier L, et al. Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura. Blood 2018. doi: 10.1182/ blood-2018-04-840090.

  47. Wong RSM, Saleh MN, Khelif A, Salama A, Portella MS, Burgess P, et al. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study. Blood 2017;130(23):2527-2536. doi: 10.1182/blood-2017-04-748707.

  48. Tersteeg C, Roodt J, Van Rensburg WJ, Dekimpe C, Vandeputte N, Pareyn I, et al. N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood 2017;129:1030-1038. doi: 10.1182/ blood-2016-09-738856.




2020     |     www.medigraphic.com